Analysis of the expression of TLR-2, -3, -4, and -9 receptors on CD3-CD56+ and CD3+CD56+ cells in different disease stages revealed clear differences in expression levels depending on disease stage, which may indicate enhanced immune activation in more advanced stages of GC. This evidence concerns the gene NCAM1 and gastric cancer.